$0 Co-pay Program

Eligible patients may qualify for a $0 co-pay for once-daily Oxtellar XR®*

+ Learn More
*Click here for Terms & Conditions.

References

  1. Data on file. Supernus Pharmaceuticals, Inc. Rockville MD.
  2. French JA, Baroldi P, Brittain ST, Johnson JK; on behalf of the PROSPER Investigators Study Group. Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. Acta Neurol Scand. 2014;129:143-153.
  3. Oxtellar XR [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.; December 2015.